glp-1 obesity drug news oct 21 2025 Trump plan on weight loss drugs fails Americans GLP-1 Pipeline Update: August 2025

Moreover, GLP-1 RAs have been shown to reduce the accumulation of -synuclein and its phosphorylated forms, thereby mitigating their toxic effects [78]

8 This suggests that GLP-1RAs can be beneficial in stabilising high-risk HFpEF patients and reducing subsequent exacerbations

Therefore, the administration of LY3437943 induces a decrease in body weight and shows a safety and tolerability profile similar to other incretins in humans as well

Similar content being viewed by others Introduction Alzheimers disease (AD) The global increase in the prevalence of neurodegenerative diseases, particularly AD and PD, as a result of an aging population poses a significant challenge to health-care systems worldwide [1, 2]

Additionally, serious adverse events requiring emergent treatment, such as hypersensitivity reactions, occurred at a higher rate in patients receiving combination therapy [9, 26]

Porcheray F, Viaud S, Rimaniol AC, et al